MEDIWOUND LTD (MDWD) Stock News
NASDAQ:MDWD - Nasdaq - IL0011316309 - Common Stock - Currency: USD
MDWD Latest News, Press Releases and Analysis
MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
YAVNE, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue...
Urban Outfitters To Rally Around 47%? Here Are 10 Top Analyst Forecasts For Wednesday
MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update
MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update
EscharEx IND Submission by Year-End; Phase 3 Study to Begin Shortly Thereafter; KOL Event Set for January 8, 2025 FDA Approves NexoBrid for Pediatric...
MediWound to Report Third Quarter 2024 Financial Results
Conference Call and Webcast Scheduled for Tuesday, November 26, 2024, at 8:30 a.m. Eastern Time
MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers
Secured additional R&D collaborations with Solventum and Mölnlycke for optimal trial consistency and patient outcomes Study to support EscharEx® BLA...
MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit
MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference
MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference
YAVNE, Israel, Sept. 03, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue...
MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns
Approval Helps Solidify NexoBrid’s Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages
MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns
Approval Helps Solidify NexoBrid’s Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages...
MDWD Stock Earnings: MediWound Misses EPS, Beats Revenue for Q2 2024
MDWD stock results show that MediWound missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
MDWD Stock Earnings: MediWound Misses EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips MediWound (NASDAQ:MDWD) just reported results for the second quarter of 2024.Me...
MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update
MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update
Completed Construction of New NexoBrid® Manufacturing Facility €16.25 Million EIC Funding Expedites EscharEx® Development for Diabetic Foot Ulcers,...
MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)
NEXT Confirms NexoBrid's Proven Safety and Efficacy in Eschar Removal, Significantly Reducing Surgical Procedures for Burn Patients
MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)
NEXT Confirms NexoBrid's Proven Safety and Efficacy in Eschar Removal, Significantly Reducing Surgical Procedures for Burn Patients...
MediWound to Report Second Quarter 2024 Financial Results
Conference Call and Webcast Scheduled for Wednesday, August 14th at 8:30 am Eastern Time
MediWound to Report Second Quarter 2024 Financial Results
Conference Call and Webcast Scheduled for Wednesday, August 14th at 8:30 am Eastern Time...
MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers
MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers
Research Published in THE LANCET's eClinicalMedicineEscharEx® Outperforms Non-Surgical Standard of Care in Debridement and Promotion of Healthy Granulation...
MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program
MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program
Funds to be used for clinical development of EscharEx® to treat diabetic foot ulcers (DFUs) Award advances MediWound’s DFU program and its future...
Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd
/PRNewswire/ -- Mölnlycke Health Care, a world-leading MedTech company specialising in solutions for wound care and surgical procedures, announced today an...
MediWound Announces $25 Million Strategic Private Placement Financing
Mölnlycke Health Care, a global leader in innovative wound care solutions, leads the PIPE with a $15 million investment
MediWound Announces $25 Million Strategic Private Placement Financing
Mölnlycke Health Care, a global leader in innovative wound care solutions, leads the PIPE with a $15 million investment...
MDWD Stock Earnings: MediWound Beats EPS, Beats Revenue for Q1 2024
MDWD stock results show that MediWound beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
MediWound Reports First Quarter 2024 Financial Results and Provides Company Update
MediWound Reports First Quarter 2024 Financial Results and Provides Company Update
NexoBrid® interest surges; $5 million in Q1 2024 revenue, with $24 million forecast for the year Manufacturing facility on target for completion by...
MediWound to Report First Quarter 2024 Financial Results
Conference Call and Webcast Scheduled for Wednesday, May 29th at 8:30 am Eastern Time
MediWound to Report First Quarter 2024 Financial Results
Conference Call and Webcast Scheduled for Wednesday, May 29th at 8:30 am Eastern Time...